Search Results
Your search for The,The matches 34670 pages
Showing 25101 - 25150
Andrea F. Patenaude, PhD, on Standards for Psychosocial Care of Children With Cancer
Andrea F. Patenaude, PhD, of Dana-Farber Cancer Institute, discusses the challenges to implementing standards for pediatric and adolescent psycho-oncology and looks ahead at next steps in the field.
Christopher J. Recklitis, PhD, MPH, on The Risk of Suicide After a Cancer Diagnosis
Christopher J. Recklitis, PhD, MPH, of the Dana-Farber Cancer Institute, discusses what is known about suicide after cancer, the risks faced by prostate cancer patients within the first year after diagnosis, and challenges across the treatment trajectory
Julia H. Rowland, PhD, on The Psychosocial Challenges Cancer Survivors Face
Julia H. Rowland, PhD, of the National Cancer Institute, discusses the growing number of promising interventions to improve health and function for those living with and beyond a cancer diagnosis, as well as those who care for and about them.
Lori Wiener, PhD, DCSW, LCSW-C, and Karen Fasciano, PsyD, on Psycho-Oncology: Where the Field Is Headed
Lori Wiener, PhD, DCSW, LCSW-C, of the National Cancer Institute, and Karen Fasciano, PsyD, of the Dana-Farber Cancer Institute, discuss the challenges of the art and science of psycho-oncology.
Lori Wiener, PhD, DCSW, LCSW-C, and Paul B. Jacobsen, PhD, on IPOS-APOS Themes of This Year’s Meeting
Lori Wiener, PhD, DCSW, LCSW-C, of the National Cancer Institute, and Paul B. Jacobsen, PhD, of the Moffitt Cancer Center, discuss the highlights of this year’s meeting, which for the first time brings together the international and American psychosocial oncology societies.
Bradley J. Zebrack, PhD, and Ursula Sansom-Daly, PhD, on Global Psychosocial Standards of Care for Adolescents and Young Adults With Cancer
Bradley J. Zebrack, PhD, of the University of Michigan School of Social Work, and Ursula Sansom-Daly, PhD, of the University of New South Wales, talk about providing supportive care services that meet the unique needs of adolescents and young adults with cancer.
Ramaswamy Govindan, MD: Roundup of Lung Cancer Findings
Ramaswamy Govindan, MD, of Washington University, summarizes three important papers: ROVA-T in relapsed and refractory small cell lung cancer, genomic characterization of large-cell neuroendocrine tumors, and the ECOG study on bevacizumab following chemotherapy for resected non–small cell lung...
Guneet Walia, PhD, on Central Issues in Lung Cancer Care
Guneet Walia, PhD, of the Lung Cancer Foundation, summarizes some key presentations: bridging the quality chasm, patients’ attitudes and physicians’ perceptions on maintenance therapy, and patient advocacy.
Jennifer King, PhD: Scientific Perspectives From the Lung Cancer Alliance
Jennifer King, PhD, of the Lung Cancer Alliance, gives her perspective on major themes of this year’s meeting: the stigma of lung cancer, the changing face of who is affected, early detection, and advances in immunotherapy.
Everett E. Vokes, MD, on Controversies in Stage IIIA Disease
Everett E. Vokes, MD, of the University of Chicago, summarizes expert views on treating stage IIIA disease: decision-making in selecting patients for surgery; multiple-modality choices; and using induction chemotherapy (Abstract ED10).
Nagashree Seetharamu, MD, on Anti-Glycan Antibody Profiling in De Novo Stage IV Non Small Cell Lung Cancer
Nagashree Seetharamu, MD, of the North Shore LIJ Health System, discusses serum AGA-signatures that may provide a minimally invasive test for early detection of lung cancer risk (Abstract P3.04-085).
William D. Travis, MD, on Pathology and Genetics of Lung Tumors: 2015 WHO Classification
William D. Travis, MD, of Memorial Sloan Kettering Cancer Center, gives an update on the WHO classification, which is crucial for optimal personalized treatment of lung cancer patients (Abstract PLEN02.01).
Fred R. Hirsch, MD, PhD, and Paul A. Bunn, Jr., MD, on the Highlights of the World Conference on Lung Cancer
Fred R. Hirsch, MD, PhD, of the University of Colorado Health Science Center, and Paul A. Bunn, Jr, MD, of the University of Colorado Cancer Center, give their views on the goals and important presentations of the 2015 World Conference on Lung Cancer.
Karen Kelly, MD, on PD-1 Axis Inhibition and the Treatment of Advanced Disease
Karen Kelly, MD, of the University of California, Davis, summarizes three important papers on NSCLC: expression as a predictive biomarker; pembrolizumab, immune-mediated adverse events, and corticosteroid use; and an evaluation of disease-related symptoms in patients treated with nivolumab or...
Philip Bonomi, MD, on Results of the Romana 1 and Romana 2 Trials
Philip Bonomi, MD, of Rush Medical College, summarizes the findings on anamorelin and its use in advanced NSCLC for improvement in anorexia/cachexia symptoms (Abstracts ORAL 29.01, ORAL 29.02).
Ugo Pastorino, MD, on Reducing Lung Cancer Mortality
Ugo Pastorino, MD, of the Istituto Nazionale dei Tumori Foundation, discusses his study, which showed that stopping smoking before or during low-dose computed tomography screening reduced overall mortality by more than 25%, a benefit that is three- to fivefold greater than this type of screening...
Pasi A. Jänne, MD, PhD, on Integration of Next Generation Data Into the Clinic
Pasi A. Jänne, MD, PhD, of Dana-Farber Cancer Institute, summarizes a workshop he conducted on the state of the art in next-generation sequencing of lung cancer (Abstract WS 01.07).
James R. Jett, MD, on Screening With Early CDT and CT
James R. Jett, MD, of National Jewish Health, discusses his study of the early CDT-Lung biomarker. His hypothesis: When used in combination with low-dose CT in screening of a high-risk population, this biomarker would increase the detection of early-stage lung cancer (Abstract MINI 12.11).
Vassiliki Papadimitrakopoulou, MD, on The Lung MAP Clinical Trial
Vassiliki Papadimitrakopoulou, MD, of MD Anderson Cancer Center, discusses the ways in which patients, investigators, and pharmaceutical companies are working together to accelerate research and access to care (Abstract MTE 02.01).
James L. Mulshine, MD, on Lung Cancer Screening in the United States: Can It Happen?
James L. Mulshine, MD, of Rush University Medical Center, discusses the profound challenges of implementing national CT screening to ensure delivery of high-quality, best-practice early lung cancer detection in the target population of tobacco-exposed individuals (Abstract MS 15.01).
Christine D. Berg, MD, on Screening for Lung Cancer in Those at High Risk
Christine D. Berg, MD, of Johns Hopkins Medicine, discusses how increased insurance coverage should dramatically increase lung cancer screening. If done correctly—which will be a challenge—screening will help improve the prognosis of patients with lung cancer (Abstract PLEN 01.01).
Heather A. Wakelee, MD, on Results of the E1505 Clinical Trial
Heather A. Wakelee, MD, of Stanford University discusses the study that explored the question of whether adding bevacizumab to adjuvant chemotherapy is beneficial in the setting of resected non–small cell lung cancer (Abstract PLEN04.03).
Tony Mok, MD, and Fred R. Hirsch, MD, PhD: Summary of the IASLC Presidential Symposium
Tony Mok, MD, of The Chinese University of Hong Kong, and Fred R. Hirsch, MD, PhD, of University of Colorado Health Science Center discuss the highlights of the featured plenary session, which included the conference’s top four abstracts (Abstract PLEN04).
Roy S. Herbst, MD, PhD, on Results From SWOG S0819
Roy S. Herbst, MD, PhD, of the Smilow Cancer Hospital at Yale Cancer Center, discusses his findings of a phase III study comparing carboplatin/paclitaxel or carboplatin/paclitaxel/bevacizumab with or without concurrent cetuximab in advanced non–small cell lung cancer (Abstract PLEN04.01).
Silvia Novello, MD, PhD: Lung Cancer Is a Women's Disease Too
Silvia Novello, MD, PhD, of the University of Turin, discusses a much-neglected aspect of lung cancer: It is not just the province of men; women are affected in great numbers as well.
Barbara J. Gitlitz, MD: Genomics of Young Lung Cancer Study
Barbara J. Gitlitz, MD, of USC/Norris Cancer Center, discusses the first prospective study on the genomic drivers and demographics of lung cancer in patients under 40 who took part in the study remotely via the Internet (Abstract ORAL22.05).
Howard Jack West, MD, on New Kinase Targets for Treating Advanced NSCLC
Howard Jack West, MD, of the Swedish Cancer Institute, summarizes three important papers: anlotinib as third-line treatment for refractory advanced non–small cell lung cancer; the EGFR exon 20 mutation as a prognostic/predictive biomarker; and EGFR exon 18 mutations as molecular predictors of...
Eric Lim, MD, on Increasing Incidence of Non-Smoking Lung Cancer
Eric Lim, MD, of the Royal Brompton and Harefield NHS Trust, discusses his findings on the nonspecific symptoms of never-smokers, which suggests that imaging could play a more important role in diagnosing these patients at an earlier stage.
M. Catherine Pietanza, MD, on A Promising New Agent for SCLC
M. Catherine Pietanza, MD, of Memorial Sloan Kettering Cancer Center, discusses rovalpituzumab tesirine, a promising DLL3-targeted antibody drug conjugate, the first precision treatment for small cell lung cancer (Abstract 7LBA).
Benjamin Besse, MD, PhD, and Tony Mok, MD, on Results of the BIRCH Clinical Trial
Benjamin Besse, MD, PhD, of the Institut Gustave Roussy, and Tony Mok, MD, of The Chinese University of Hong Kong, discuss this phase II trial of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1–selected NSCLC (Abstract 17LBA).
Federico Cappuzzo, MD, and Tony Mok, MD, on Managing EGFR Resistance in Lung Cancer
Federico Cappuzzo, MD, of Istituto Toscano Tumori-Ospedale Civile Livorno, and Tony Mok, MD, of The Chinese University of Hong Kong, discuss current strategies for treating patients with acquired resistance, and what the future holds for these patients.
Michel Ducreux, MD, PhD, on Results of the Phase II COLO 001 Clinical Trial
Michel Ducreux, MD, PhD, of the Institut Gustave Roussy, discusses the efficacy and safety in this study of nab-paclitaxel in patients with previously treated metastatic colorectal cancer (Abstract 2131).
Christoph Zielinski, MD: Highlights of 2015 European Cancer Congress
As Chair of the ECC Local Organizing Committee, Christoph Zielinski, MD, of the Medical University Vienna - General Hospital, shares his thoughts on the important goals and presentations of the 2015 Congress.
Jonathan E. Rosenberg, MD, on Results of the IMvigor 210 Study on Atezolizumab in Locally Advanced or Metastatic Urothelial Cancer
Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, discusses this pivotal study of an investigational immunotherapy that has shown increased and durable responses, with a relatively benign toxicity profile (Abstract 21LBA).
Mary K. Gospodarowicz, MD, on Challenges in Cancer Control
Mary K. Gospodarowicz, MD, of Princess Margaret Hospital, discusses the work of the Global Task Force on Radiotherapy for Cancer Control and its efforts to improve access to vital radiation treatment worldwide, especially in low- and middle-income countries.
Cora N. Sternberg, MD, on New Targets in Renal Cell Carcinoma
Cora N. Sternberg, MD, of San Camillo Forlanini Hospital, summarizes a teaching lecture on new targets in renal cell carcinoma, and discusses what to expect for the future of treating RCC.
Clifford A. Hudis, MD, on Results of the TAILORx Clinical Trial
Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, discusses this prospective study of endocrine therapy alone in patients with ER-positive, HER2-negative, node-negative breast cancer (Abstract 5BA).
Frederic Amant, MD, PhD, on Cancer and Pregnancy
Frederic Amant, MD, PhD, of the Katholieke Universiteit Leuven, discusses the important decisions that must be made when a woman is diagnosed with cancer while pregnant: Should treatment be delayed or the pregnancy terminated?
Looking Ahead With the New ECCO President: Peter L. J. Naredi, MD, PhD
Incoming ECCO President, Peter L. J. Naredi, MD, PhD, of the University of Gothenburg, discusses his upcoming year as the new ECCO President, his vision for the organization, and his views on cancer treatment today.
Tony Mok, MD, and Alice Shaw, MD, PhD: Expert Perspectives on ALK Inhibition and Brigatinib
Tony Mok, MD, of The Chinese University of Hong Kong, and Alice Shaw, MD, PhD, of Massachusetts General Hospital, discuss the current status and future outlook of ALK inhibition, and an assessment of brigatinib CNS activity in patients with ALK-positive non-small cell lung cancer and intracranial...
A. Oliver Sartor, MD, on Results of the ALSYMPCA Trial for Castration-Resistant Prostate Cancer
A. Oliver Sartor, MD, of Tulane University School of Medicine, discusses the latest results of a clinical trial on radium-223 dichloride and the improvement in overall survival of men with advanced prostate cancer (Abstracts 2510, 2530).
Matti S. Aapro, MD, on Geriatric Oncology: A Multidisciplinary Approach for Positive Outcomes
Matti S. Aapro, MD, of IMO Clinique de Genolier, offered a case presentation and a cross-disciplinary approach to finding the best way to effect a cure with minimal impact on quality of life.
Matteo Lambertini, MD, on Preserving Women’s Fertility Through Hormonal Therapy
Matteo Lambertini, MD, Dana-Farber Cancer Institute, discusses the use of LHRH agonists during chemotherapy to suppress ovarian function as a way to preserve fertility in breast cancer patients (Abstract 1957).
Shailender Bhatia, MD, on Merkel Cell Carcinoma: Final Results of a Phase II Study
Shailender Bhatia, MD, of the Fred Hutchinson Cancer Center, discusses his paper on interleukin-12 DNA and regression of Merkel cell tumors (Abstract 504).
Michael Pfreundschuh, MD, on Treating Lymphoid Malignancies in Children and Adults With the Same Protocols
Michael Pfreundschuh, MD, of Universitaetsklinikum des Saarlandes, summarizes a session he chaired on this topic, which covered Burkitt’s lymphoma as well as lymphoblastic leukemia in children and adults.
Ignacio Melero, MD, PhD, on Developing and Implementing New Immunotherapies
Ignacio Melero, MD, PhD, of the University Clinic of Navarra, Centre of Applied Medical Research, discusses the latest developments in an important cancer treatment avenue.
Jean-Charles Soria, MD, PhD, on Results of the KEYNOTE 001 Clinical Trial
Jean-Charles Soria, MD, PhD, of Gustave Roussy, summarizes an important study: the efficacy and safety of pembrolizumab in previously treated non-small cell lung cancer (Abstract LBA33).
Jean-Charles Soria, MD, PhD, on Results of the Lux Lung 8 Clinical Trial
Jean-Charles Soria, MD, PhD, of Gustave Roussy, summarizes an important study: afatinib vs erlotinib in squamous cell carcinoma of the lung.
Martine J. Piccart-Gebhart, MD, PhD, on Reducing the Cost and Increasing Access to Cancer Drugs
Martine J. Piccart-Gebhart, MD, PhD, of the Jules Bordet Institute, discusses the ESMO initiative to make cancer drugs affordable.
Brian I. Rini, MD, on A Cancer Vaccine for Renal Cell Carcinoma
Brian I. Rini, MD, of the Cleveland Clinic Taussig Cancer Institute, discusses the results from a phase III study investigating a multipeptide cancer vaccine in patients receiving sunitinib as first-line therapy for advanced/metastatic renal cell carcinoma (Abstract 17LBA).
